AgingResearch.NewsJoin free

Atovaquone + proguanil

Atovaquone + proguanil has been studied in 2 papers since 2025: 2 observational studies in people; 1 in the past year. The newest story, Oct 30, 2026: “Two parasite-fighting drugs linked to lower risk of death”.

Intervention

2 papers study it3 findingsUpdated

PubChemPubChemChEBIChEBI

1 new paper in 30 daysSee all 2

“were associated with consistent reductions in all-cause mortality across cohorts”
Antiprotozoal drug exposure and reduced long-term mortality and morbidity: a multi-cohort pharmacoepidemiologic studyFrontiers in pharmacology2026doi:10.3389/fphar.2026.1861376

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 2 more
  • Humans2

What is Atovaquone + proguanil linked with?

3

Studies link Atovaquone + proguanil with 3 measures, most often incidence of multiple age-related conditions (1 study), mortality (1) and survival (1).

Incidence of multiple age-related conditions

downin humans1

1 study

  1. Atovaquone + proguanil is associated with incidence of multiple age-related conditions in humans.

    “lower incidence of multiple age-related conditions, including dementia, diabetes mellitus, cardiovascular disease, chronic kidney disease, and selected malignancies.”

    Humans

    Two parasite-fighting drugs linked to lower risk of death

    Frontiers in pharmacology

Mortality

downin humans1

1 study

  1. Atovaquone + proguanil is associated with mortality in humans.

    “were associated with consistent reductions in all-cause mortality across cohorts”

    Humans

    Two parasite-fighting drugs linked to lower risk of death

    Frontiers in pharmacology

Survival

upin humans1

1 study

  1. Atovaquone + proguanil is associated with survival in humans.

    “identified two antiprotozoals, atovaquone-proguanil and mefloquine, that were associated with increased survival.”

    Humans

    Antiprotozoal medications associated with increased longevity and reduced morbidity in two national cohorts

    medRxiv : the preprint server for health sciencesPreprint

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Frontiers in Pharmacology

Two parasite-fighting drugs linked to lower risk of death

An observational cohort compared 3,876 people exposed to two parasite-fighting drugs with 77,520 matched controls, finding links to lower mortality and fewer age-related…An observational cohort compared 3,876 people exposed to two parasite-fighting drugs with 77,520 matched controls, finding links to lower mortality and fewer age-related conditions.

Cohort · 3,876 peoplePopulations
Paper

Related